SCHEMBL22636768

SCHEMBL22636768

N#Cc1cc(N)c(Br)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.39
KHK P50053 1/20 0.35
PGK1 P00558 1/20 0.35
VCAM1 P19320 1/20 0.34
MEN1 O00255 3/20 0.33
MAPT P10636 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
CSNK1A1 P48729 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
IDO1 P14902 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 2/20 0.33
APAF1 O14727 1/20 0.32
POLB P06746 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20517749 0.92 TRPV4 (0.39) TRPV4KHKPGK1VCAM1MEN1
SCHEMBL15407630 0.83 GAA (0.44) TRPV4KHKVCAM1MEN1MAPT
SCHEMBL9460722 0.82 MEN1 (0.41) KHKMEN1MAPTKMT2AGAA
SCHEMBL1291792 0.82 GAA (0.46) TRPV4KHKPGK1VCAM1MEN1
SCHEMBL31314338 0.80 GAA (0.50) TRPV4KHKPGK1VCAM1MEN1
SCHEMBL25235179 0.76 TRPV4 (0.43) TRPV4PGK1VCAM1MEN1KMT2A
SCHEMBL7073779 0.76 GAA (0.57) TRPV4KHKPGK1VCAM1MEN1
SCHEMBL30498666 0.76 GAA (0.57) TRPV4KHKPGK1VCAM1MEN1
SCHEMBL22637057 0.75 TRPV4 (0.45) TRPV4KHKMEN1MAPTKMT2A
SCHEMBL2479059 0.75 ALDH1A1 (0.46) TRPV4KHKPGK1VCAM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377084-B2 ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2025-08-05 US disclosed
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20230000851-A1 ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2023-01-05 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
EP-4058429-A1 ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-09-21 EP disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
WO-2021094763-A1 ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2021-05-20 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 TRPV4 4394/4885KHK 2697/4885PGK1 3616/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 TRPV4 4371/4885KHK 2879/4885PGK1 3363/4885
US-12377084-B2 ERAP1 modulators ERAP1, NR1I3, HRH4 TRPV4 1187/4885KHK 3514/4885PGK1 3793/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 TRPV4 4279/4885KHK 2717/4885PGK1 3500/4885
US-20230000851-A1 ERAP1 MODULATORS ERAP1, NR1I3, HRH4 TRPV4 1187/4885KHK 3514/4885PGK1 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.